gene and environment–gene interaction analysis, and potentially important missed health information. The next trap is non-personalised interpretation. The conclusions are based on gene results only, without taking into account individual data, which is a serious mistake in anti-ageing and preventive genomics. Indeed, these particular preventive ‘modulator of risk’ genes have only a 10–15% impact on the final result and cannot be interpreted alone. Nevertheless, the majority of standard reports include just gene characteristics and partial, often simplistic, descriptive scientific data, which does not correspond to evidence- based medicine criteria. Interestingly, the same data can be easily found using a google search, free of charge, and therefore, cannot be considered personalised. Finally, the third trap is speculation with regard to scientific data. Single descriptive articles are often used to justify the tests of some genes; nevertheless, it has no credibility or evidence base. Only around 0.04% of all published articles can be considered clinically credible for practice. Indeed, genetic marketing usually neglects to inform the customer correctly.
In this context, the highly personalised approach of BARANOVA MONACO® has become requested all the more. Can you tell us about its practical applications? The approach of BARANOVA MONACO® is an holistic and highly personalised epigenomic method, which not only analyses single genes, but also gene–gene and environment–gene interactions, including detailed individual and clinical data. Furthermore, BARANOVA MONACO’s unique ‘Programmes for Life’® always includes aspects of functional medicine with regard to the revealed genomic data. New epigenomic recommendations based on the optimisation of gene activity contain qualitative and quantitative information for each particular case. We are able to obtain high clinical efficiency in
patients with the help of these programmes, which explains the increase in requests in new countries.
Such requests and the current situation in genomics has pushed me to accept and consult with an increasing number of patients and clinics. I really like to help people — both patients and physicians — to avoid becoming ‘victims’ of DNA business. Interestingly, there are also increased requests for previously tested patients by other companies, who do not really know what to do with their results.
Which other countries and centres you are working with? BARANOVA MONACO® collaborates with a number leading clinics. At present we have many requests coming from Russia and the Middle East, as well as Switzerland, France, the United States and, of course, Monaco. We are open for collaboration with reliable partners — clinics and advanced spas — interested in highly personalised approaches to anti-ageing and personalised medicine.
Can you tell us more about the BARANOVA MONACO® range of food supplements? This very special, new nutraceutic line, called geneceuticals® owing to its profound capabilities, has been created according to unique formulae, using specific quantum genomics know-how to increase the efficiency of the ingredients used and to optimise gene expression, creating a strong personalised anti- ageing effect. Special BARANOVA MONACO®
protocols are developed and applied for the correct use of this powerful tool. Furthermore, I am deeply convinced that personalised prevention and anti-ageing should
bring pleasure and beauty to our lives. For this reason, this special design has been developed, and this product line has become not only highly effective, but also one of the first real luxury lines in this sector of activity. Products are available via the internet www.
regeneproducts.com.
Further information
www.baranovamonaco.com;
baranova.monaco@
gmail.com
prime-journal.com | March 2013 ❚
107
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140